WO2005025649A1 - Membrane a fibres creuses de permeation selective a base de polysulfone et son procede de production - Google Patents
Membrane a fibres creuses de permeation selective a base de polysulfone et son procede de production Download PDFInfo
- Publication number
- WO2005025649A1 WO2005025649A1 PCT/JP2004/011972 JP2004011972W WO2005025649A1 WO 2005025649 A1 WO2005025649 A1 WO 2005025649A1 JP 2004011972 W JP2004011972 W JP 2004011972W WO 2005025649 A1 WO2005025649 A1 WO 2005025649A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hollow fiber
- fiber membrane
- membrane
- blood
- spinning
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 352
- 239000012510 hollow fiber Substances 0.000 title claims abstract description 250
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 229920002492 poly(sulfone) Polymers 0.000 title claims description 18
- 238000009987 spinning Methods 0.000 claims abstract description 163
- 210000004369 blood Anatomy 0.000 claims abstract description 129
- 239000008280 blood Substances 0.000 claims abstract description 129
- 238000005345 coagulation Methods 0.000 claims abstract description 113
- 230000015271 coagulation Effects 0.000 claims abstract description 113
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 103
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 73
- 229920001600 hydrophobic polymer Polymers 0.000 claims abstract description 55
- 230000002829 reductive effect Effects 0.000 claims abstract description 44
- 229920000642 polymer Polymers 0.000 claims abstract description 37
- 239000000243 solution Substances 0.000 claims description 122
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 41
- 239000011550 stock solution Substances 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 25
- 238000000746 purification Methods 0.000 claims description 23
- 238000001179 sorption measurement Methods 0.000 claims description 23
- 238000010438 heat treatment Methods 0.000 claims description 17
- 230000035699 permeability Effects 0.000 claims description 14
- 230000010412 perfusion Effects 0.000 claims description 13
- 229940057995 liquid paraffin Drugs 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 238000007654 immersion Methods 0.000 claims description 8
- 102000036675 Myoglobin Human genes 0.000 claims description 6
- 108010062374 Myoglobin Proteins 0.000 claims description 6
- 210000002196 fr. b Anatomy 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 239000004695 Polyether sulfone Substances 0.000 claims description 5
- 229920006393 polyether sulfone Polymers 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 235000015278 beef Nutrition 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000000644 isotonic solution Substances 0.000 claims description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims 1
- 210000000540 fraction c Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 26
- 239000000463 material Substances 0.000 abstract description 14
- 230000002209 hydrophobic effect Effects 0.000 abstract description 6
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 60
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 60
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 48
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 48
- 239000007788 liquid Substances 0.000 description 40
- 239000011148 porous material Substances 0.000 description 33
- 238000010828 elution Methods 0.000 description 31
- 238000001035 drying Methods 0.000 description 30
- 230000003068 static effect Effects 0.000 description 28
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 27
- 239000007864 aqueous solution Substances 0.000 description 24
- 235000011187 glycerol Nutrition 0.000 description 24
- 239000010935 stainless steel Substances 0.000 description 23
- 229910001220 stainless steel Inorganic materials 0.000 description 23
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 21
- 238000005406 washing Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000000306 component Substances 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000003379 elimination reaction Methods 0.000 description 14
- 230000008030 elimination Effects 0.000 description 13
- 230000014759 maintenance of location Effects 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 230000005611 electricity Effects 0.000 description 12
- 230000001112 coagulating effect Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000012503 blood component Substances 0.000 description 10
- 239000012535 impurity Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000002615 hemofiltration Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 238000005191 phase separation Methods 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000005245 sintering Methods 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001891 gel spinning Methods 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229910018879 Pt—Pd Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000004760 aramid Substances 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
- B01D67/0011—Casting solutions therefor
- B01D67/00113—Pretreatment of the casting solutions, e.g. thermal treatment or ageing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
- B01D67/0011—Casting solutions therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/66—Polymers having sulfur in the main chain, with or without nitrogen, oxygen or carbon only
- B01D71/68—Polysulfones; Polyethersulfones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/20—Specific permeability or cut-off range
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Le problème posé par l'invention est l'obtention d'un épurateur de sang de type à fibres creuses ayant un polymère hydrophobe et un polymère hydrophile, présentant une quantité réduite de matière éluée d'une membrane, une excellente sécurité, une instabilité réduite de fonctionnement due au contact avec le sang et une excellente compatibilité avec le sang. Pour résoudre les problèmes posés ci-dessus, l'invention présente une membrane à fibres creuses présentant une grande uniformité de structure de membrane ainsi que des trous dans une surface intérieure, un bon équilibre de propriétés hydrophile et hydrophobe, une faible quantité de matière éluée de la membrane et une excellente compatibilité avec le sang, dans le cas où la composition polymère optimale est sélectionnée pour un fluide de filage contenant un polymère hydrophobe et un polymère hydrophile dissous dans celui-ci, la relation établissant que la vitesse linéaire de décharge de l'agent de formation de creux > la vitesse linéaire de décharge d'un fluide de filage est satisfaite lorsque le fluide de filage est déchargé par un ajutage avec l'agent de formation de creux et introduit dans un bain de coagulation par une partie d'espace, et une membrane à fibres creuses est coagulée tout en étant étirée dans le bain de coagulation.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003208484A JP4093134B2 (ja) | 2003-08-22 | 2003-08-22 | 中空糸型血液浄化膜 |
| JP2003-208484 | 2003-08-22 | ||
| JP2003-308980 | 2003-09-01 | ||
| JP2003308980A JP2005074019A (ja) | 2003-09-01 | 2003-09-01 | 中空糸型血液浄化膜 |
| JP2003354798A JP4381088B2 (ja) | 2003-10-15 | 2003-10-15 | 血液適合性中空糸型膜およびその製造方法 |
| JP2003-354798 | 2003-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005025649A1 true WO2005025649A1 (fr) | 2005-03-24 |
Family
ID=34317208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2004/011972 WO2005025649A1 (fr) | 2003-08-22 | 2004-08-20 | Membrane a fibres creuses de permeation selective a base de polysulfone et son procede de production |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2005025649A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006304827A (ja) * | 2005-04-26 | 2006-11-09 | Toyobo Co Ltd | 血液浄化器 |
| EP2545986A4 (fr) * | 2010-03-09 | 2015-05-06 | Toyo Boseki | Membrane capillaire poreuse destinée au traitement d'un liquide contenant des protéines |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06296686A (ja) * | 1993-04-19 | 1994-10-25 | Asahi Chem Ind Co Ltd | 医療用ポリスルホン中空糸膜 |
| JPH09154936A (ja) * | 1994-12-16 | 1997-06-17 | Toyobo Co Ltd | 血液浄化用モジュール、血液浄化膜及びその製造方法 |
| JPH09220455A (ja) * | 1996-10-04 | 1997-08-26 | Toyobo Co Ltd | 中空糸型選択分離膜 |
| JPH10108907A (ja) * | 1996-10-08 | 1998-04-28 | Toyobo Co Ltd | 血液浄化膜、その製造方法及び血液浄化用モジュール |
| JP3253861B2 (ja) * | 1996-08-28 | 2002-02-04 | 帝人株式会社 | 選択透過性中空糸膜 |
| WO2002009857A1 (fr) * | 2000-07-27 | 2002-02-07 | Asahi Medical Co., Ltd. | Membrane de fibres creuses modifiées |
-
2004
- 2004-08-20 WO PCT/JP2004/011972 patent/WO2005025649A1/fr active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06296686A (ja) * | 1993-04-19 | 1994-10-25 | Asahi Chem Ind Co Ltd | 医療用ポリスルホン中空糸膜 |
| JPH09154936A (ja) * | 1994-12-16 | 1997-06-17 | Toyobo Co Ltd | 血液浄化用モジュール、血液浄化膜及びその製造方法 |
| JP3253861B2 (ja) * | 1996-08-28 | 2002-02-04 | 帝人株式会社 | 選択透過性中空糸膜 |
| JPH09220455A (ja) * | 1996-10-04 | 1997-08-26 | Toyobo Co Ltd | 中空糸型選択分離膜 |
| JPH10108907A (ja) * | 1996-10-08 | 1998-04-28 | Toyobo Co Ltd | 血液浄化膜、その製造方法及び血液浄化用モジュール |
| WO2002009857A1 (fr) * | 2000-07-27 | 2002-02-07 | Asahi Medical Co., Ltd. | Membrane de fibres creuses modifiées |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006304827A (ja) * | 2005-04-26 | 2006-11-09 | Toyobo Co Ltd | 血液浄化器 |
| EP2545986A4 (fr) * | 2010-03-09 | 2015-05-06 | Toyo Boseki | Membrane capillaire poreuse destinée au traitement d'un liquide contenant des protéines |
| US9492794B2 (en) | 2010-03-09 | 2016-11-15 | Toyobo Boseki Kabushiki Kaisha | Porous hollow fiber membrane for treatment of protein-containing liquid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6432309B1 (en) | Polysulfone-base hollow-fiber hemocathartic membrane and processes for the production thereof | |
| RU2113273C1 (ru) | Мембрана из полого волокна на основе полисульфона и способ ее производства | |
| KR100869203B1 (ko) | 비대칭 다공질막 및 그의 제조 방법 | |
| CA2095423A1 (fr) | Methode hautement efficiente d'extraction du ldl-cholesterol du sang | |
| JPWO2002009857A1 (ja) | 改質された中空糸膜 | |
| JP5857407B2 (ja) | 中空糸膜および中空糸膜の製造方法 | |
| RU2667068C2 (ru) | Пористая мембрана, модуль очистки крови, содержащий пористую мембрану, и способ получения пористой мембраны | |
| JP4873665B2 (ja) | 血液浄化用中空糸膜 | |
| JPH06296686A (ja) | 医療用ポリスルホン中空糸膜 | |
| JP3934340B2 (ja) | 血液浄化器 | |
| JPH10230148A (ja) | 半透膜 | |
| JPH10180058A (ja) | 中空糸膜 | |
| WO2005025649A1 (fr) | Membrane a fibres creuses de permeation selective a base de polysulfone et son procede de production | |
| JP4381088B2 (ja) | 血液適合性中空糸型膜およびその製造方法 | |
| JPH0970431A (ja) | ポリスルホン系中空糸型人工腎臓の製造方法および人工腎臓 | |
| JP5062773B2 (ja) | 血液浄化器 | |
| JP4093134B2 (ja) | 中空糸型血液浄化膜 | |
| JP4381058B2 (ja) | 血液適合性に優れた中空糸型血液浄化器 | |
| JPH07289866A (ja) | ポリスルホン系選択透過膜 | |
| JP4388302B2 (ja) | 血液適合性に優れた中空糸型血液浄化器 | |
| JP4190445B2 (ja) | 蛋白吸着量が少ない中空糸型血漿成分分離器 | |
| JP7131038B2 (ja) | 腹水濾過用の中空糸膜 | |
| JP4882518B2 (ja) | 医療用分離膜および医療用分離膜モジュールの製造方法 | |
| JP4386607B2 (ja) | ポリスルホン系血液浄化膜の製造方法およびポリスルホン系血液浄化膜 | |
| JP2005087350A (ja) | 血液適合性に優れた血液浄化膜 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NA NI NO NZ OM PG PL PT RO RU SC SD SE SG SK SL SY TM TN TR TT TZ UA UG US UZ VC YU ZA ZM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |